JAMA   
February 8, 2012, Vol 307, No. 6, pp 539-628
http://jama.ama-assn.org/current.dtl

Editorials
Inching Toward a Serogroup B Meningococcal Vaccine for Infants
Amanda C. Cohn, Nancy E. Messonnier
JAMA. 2012;307(6):614-615.doi:10.1001/jama.2012.118

Excerpt
In the past decade, the introduction of meningococcal conjugate vaccines has led to substantial reductions in meningococcal disease. Monovalent serogroup C vaccines have virtually eliminated serogroup C disease from the United Kingdom and other countries, and serogroup A, C, W, and Y vaccines have reduced disease among adolescents in the United States.1,2 In 2010 and 2011, Burkina Faso, Mali, Niger, and part of Nigeria introduced serogroup A conjugate vaccine, which may eliminate epidemic meningitis from the meningitis belt of Africa. These accomplishments have been dampened by the lack of effective serogroup B meningococcal vaccines. Serogroup B meningococcal disease causes substantial morbidity and mortality globally, especially in young infants.3,4,5 Serogroup B disease can be devastating; 5% to 10% of children with the disease do not survive and another 10% to 20% experience long-term sequelae such as hearing loss, limb loss, and neurologic deficits. …